Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 6/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 5/20 | 0.46 |
| ▸ | CDC25B | P30305 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976330 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10CDC25B | |
| SCHEMBL669832 | 0.81 | THRB (0.61) | KDM4EALDH1A1HPGDHSD17B10CDC25B | |
| SCHEMBL8967049 | 0.80 | ALDH1A1 (0.60) | KDM4EALDH1A1HPGDHSD17B10CDC25B | |
| SCHEMBL6987407 | 0.80 | HSD17B10 (0.56) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL8967046 | 0.78 | POLB (0.48) | KDM4EALDH1A1HPGDHSD17B10CDC25B | |
| SCHEMBL9978740 | 0.78 | MCL1 (0.60) | KDM4EALDH1A1HPGDHSD17B10CDC25B | |
| SCHEMBL27540803 | 0.77 | HSD17B10 (0.50) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL7443511 | 0.76 | DRD3 (0.54) | KDM4EALDH1A1HPGDHSD17B10CDC25B | |
| SCHEMBL1671110 | 0.76 | CYP1A1 (0.64) | KDM4EALDH1A1HPGDCDC25BNPSR1 | |
| SCHEMBL485003 | 0.75 | HSD17B10 (0.67) | KDM4EALDH1A1HPGDHSD17B10MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| CN-101478962-A | Novel CXCR2 inhibitors | SANOFI AVENTIS (FR) | 2009-07-08 | — | — | CN | disclosed |
| EP-2040688-A1 | NEW CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| CN-101094830-A | Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-26 | — | — | CN | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | KDM4E 3892/4885ALDH1A1 1443/4885HPGD 565/4885 |
| US-20090227625-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | KDM4E 3853/4885ALDH1A1 2011/4885HPGD 805/4885 |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR4 | KDM4E 3923/4885ALDH1A1 1690/4885HPGD 662/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | KDM4E 3892/4885ALDH1A1 1443/4885HPGD 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.